Salud financiera de hoja de balance de electroCore

Salud financiera controles de criterios 5/6

electroCore tiene un patrimonio de los accionistas total de $4.5M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $13.9M y $9.4M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$14.23m
Patrimonio	US$11.47m
Total pasivo	US$10.88m
Activos totales	US$22.36m

Actualizaciones recientes sobre salud financiera

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

Sep 25

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

Apr 29

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($11.7M) de ECOR superan a sus pasivos a corto plazo ($7.8M).

Pasivo a largo plazo: Los activos a corto plazo de ECOR ($11.7M) superan a sus pasivos a largo plazo ($1.6M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ECOR está libre de deudas.

Reducción de la deuda: ECOR no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ECOR tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si ECOR tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de electroCore

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore Announces Listing Transfer to the Nasdaq Capital Market

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

Recent updates

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2026

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

electroCore, Inc. to Report Q2, 2024 Results on Aug 07, 2024

electroCore, Inc., Annual General Meeting, Sep 03, 2024

electroCore Announces the Commercial Launch of TAC-STIM™?

Forecast to breakeven in 2026

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. has announced a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore sees Q3 revenue below consensus

electroCore is issued 4 new U.S. patents in nVNS therapy

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

electroCore sees Q2 revenue estimate higher than consensus

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought US$56k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Consensus EPS estimates fall by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target decreased to US$2.80

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore: Pioneering Bioelectronic Medicine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus forecasts updated

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore completes sale of $1.4M of NOL tax benefits

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients

electroCore, Inc. Develops Non-Drug and Non-Invasive Alternative to Pharmaceuticals That Safely and Effectively Stimulates the Vagus Nerve to Communicate with the Brain and Help Optimize the Body’s Own Ability to Control Problems Impacting Its Health

Price target decreased to US$3.50

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.27 loss in 1Q 2020)

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2021